<DOC>
	<DOC>NCT01661387</DOC>
	<brief_summary>As a post-approval requirement of the European Medicines Agency, this European patient post authorization safety study is an observational study being conducted to monitor the safety of long-term treatment with Plenadren and other glucocorticoid replacement therapies in routine clinical practice in patients with chronic adrenal insufficiency (primary or secondary).</brief_summary>
	<brief_title>A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)</brief_title>
	<detailed_description />
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Diagnosis of chronic adrenal insufficiency Written informed consent/assent in compliance with applicable countryspecific and local regulations Participation in an interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adrenal insufficiency</keyword>
	<keyword>DuoCort</keyword>
	<keyword>Congenital adrenal hyperplasia (CAH)</keyword>
	<keyword>Modified release</keyword>
	<keyword>Hydrocortisone</keyword>
</DOC>